A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine
NCT ID: NCT03888157
Last Updated: 2021-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
839 participants
OBSERVATIONAL
2019-03-10
2020-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
NCT02908087
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
NCT03882970
Incretin-based Therapy in Late Preclinical Type 1 Diabetes
NCT02898506
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
NCT06635057
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
NCT01654120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liraglutide
Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.
Liraglutide
Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liraglutide
Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, age greater than or equal to 18 years at the time of signing informed consent
* The decision to initiate treatment with commercially available Victoza® has been made by the patient and the treating physician before and independently from the decision to include the patient in this study
* Patients diagnosed with type 2 diabetes mellitus (T2DM), with treatment planned according to the Iranian label for Victoza® at treatment initiation
* Available glycated haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of treatment with Victoza®
Exclusion Criteria
* Known or suspected hypersensitivity to Victoza® or related products
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Reporting Anchor and Disclosure (1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Ahvāz, , Iran
Novo Nordisk Investigational Site
Ardabil, , Iran
Novo Nordisk Investigational Site
Babol, , Iran
Novo Nordisk Investigational Site
Gorgan, , Iran
Novo Nordisk Investigational Site
Hamadan, , Iran
Novo Nordisk Investigational Site
Hormozgan, , Iran
Novo Nordisk Investigational Site
Isfahan, , Iran
Novo Nordisk Investigational Site
Islamshahr, , Iran
Novo Nordisk Investigational Site
Karaj, , Iran
Novo Nordisk Investigational Site
Kerman, , Iran
Novo Nordisk Investigational Site
Mashahd, , Iran
Novo Nordisk Investigational Site
Mashhad, , Iran
Novo Nordisk Investigational Site
Sari, , Iran
Novo Nordisk Investigational Site
Shiraz, , Iran
Novo Nordisk Investigational Site
Tehran, , Iran
Novo Nordisk Investigational Site
Yazd, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1213-4238
Identifier Type: OTHER
Identifier Source: secondary_id
NN2211-4438
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.